Peptides for Becker Muscular Dystrophy: Muscle Function & Protection

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides are playing an increasingly vital role in Becker Muscular Dystrophy treatment by improving drug delivery for exon-skipping therapies and acting as myostatin inhibitors. Novel agents like Sevasemten also show promise in reducing muscle damage and protecting cardiac function.

Becker Muscular Dystrophy: A Milder, Yet Significant Challenge

Becker Muscular Dystrophy (BMD) is a progressive muscle-wasting disorder, similar to Duchenne Muscular Dystrophy (DMD) but typically with a later onset and slower progression. It results from mutations in the dystrophin gene, leading to the production of a partially functional, rather than absent, dystrophin protein. While often less severe than DMD, BMD still causes significant muscle weakness, functional decline, and cardiac complications. The therapeutic landscape for BMD is evolving, with peptides emerging as key players in enhancing existing treatments and offering new avenues for intervention.

Peptides in Exon-Skipping Strategies for BMD

Exon skipping, a therapeutic approach also utilized in DMD, aims to correct the genetic defect by enabling the production of a more functional dystrophin protein. This involves using antisense oligonucleotides (AONs) to bypass specific mutated exons in the dystrophin gene. A critical challenge in these therapies is ensuring efficient delivery of AONs to muscle cells. Peptides are proving instrumental in overcoming this hurdle. Peptide-conjugated antisense oligonucleotides (PPMOs) enhance the cellular uptake and distribution of these genetic therapies, allowing for more effective dystrophin restoration in affected muscles. This improved delivery mechanism is vital for maximizing the therapeutic benefit.

Follistatin Gene Therapy: Inhibiting Myostatin

Another significant peptide-related strategy involves Follistatin. Follistatin is a naturally occurring protein that acts as a potent inhibitor of myostatin, a protein that limits muscle growth. In BMD, where muscle integrity is compromised, inhibiting myostatin can promote muscle regeneration and increase muscle mass. Studies have shown that Follistatin gene therapy can improve ambulation in individuals with BMD by increasing skeletal muscle mass (Al-Zaidy et al., 2015). This approach offers a direct way to counteract muscle wasting by promoting an anabolic environment within the muscle.

Sevasemten: A Novel Agent for Muscle Protection

Beyond direct dystrophin modification or myostatin inhibition, other peptide-based or peptide-mimicking agents are showing promise. Sevasemten, a potential treatment for BMD, has demonstrated encouraging results in clinical trials. Phase 2 CANYON data indicated that Sevasemten reduced levels of a marker of muscle damage, suggesting a protective effect on muscle tissue (Muscular Dystrophy UK, 2024). Furthermore, Sevasemten has shown positive effects on cardiovascular markers, maintaining left ventricular ejection fraction (LVEF) stability and stable NT-proBNP levels, hinting at crucial heart protection in BMD patients (NeurologyLive, 2026). This is particularly important given the prevalence of cardiomyopathy in BMD.

Practical Takeaway for Patients

For individuals living with Becker Muscular Dystrophy, the landscape of therapeutic options is expanding, with peptides playing a central role. These advancements offer the potential for improved muscle function, reduced muscle damage, and enhanced cardiac protection. It's essential to maintain an ongoing dialogue with your neuromuscular specialist about these emerging therapies, including peptide-enhanced exon-skipping strategies, myostatin inhibitors like Follistatin, and novel protective agents such as Sevasemten. Staying informed and discussing personalized treatment plans can help optimize outcomes and improve quality of life.